Mike Castro

机构：National Institutes of Health, National Institute of Allergy and Infectious Diseases · ORCID：0000-0002-8045-1754

发表论文 33 篇 · 总被引 574 次 · h-index 10

代表论文

• Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trial (2024 · Nature Medicine · 被引 61)
• Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine (2024 · npj Vaccines · 被引 22)
• Adjuvanted SARS-CoV-2 spike protein vaccination elicits long-lived plasma cells in nonhuman primates (2024 · Science Translational Medicine · 被引 22)
• Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial (2024 · Nature Communications · 被引 21)
• Safety and pharmacokinetics of N6LS, a broadly neutralising monoclonal antibody for HIV: a phase 1, open-label, dose-escalation study in healthy adults (2025 · The Lancet HIV · 被引 10)
• Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022–23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study (2025 · The Lancet Infectious Diseases · 被引 8)